Skip to main content

Daniel Kelly Benjamin, MD, PhD

Kiser-Arena Distinguished Professor of Pediatrics
Professor of Pediatrics
Member in the Duke Clinical Research Institute
Campus mail: 7044 Duke Clinical Research Institute, 2400 Pratt St, Durham, NC 27710
Phone: (919) 668-7081

Dr. Danny Benjamin is the Principal Investigator and Chair of the National Institute of Child Health and Human Development’s Pediatric Trials Network. The Network is responsible for designing and leading clinical trials of off-patent medicines in children of all ages across all therapeutic areas. The team has established, or is actively studying, the correct dosing and safety of more than 50 of the most commonly used medicines in children. Each of these trials is conducted under an investigational new drug (IND) application with guidance from the Food and Drug Administration for labeling.

Signature programs of the Network include clinical trials in premature, term infants and most recently, obese children. Over the past 10 years, Dr. Benjamin’s group has enrolled more premature infants, at more sites, in more clinical trials of off-patent anti-infectives under an IND than all other academic medical centers, pharmaceutical companies, and government agencies in the world, combined.

Dr. Benjamin is recognized by the National Institutes of Health as a premiere mentor and educator. His research program serves as a platform to train students and early career investigators. Dr. Benjamin’s group has a clinical research summer program for high school and college students targeting under-represented minority students, and he is the primary mentor for medical students, residents, subspecialty fellows (including two T32 programs sponsored by NIH for which he is PI), and multiple junior faculty.

Dr. Benjamin has published over 250 works with up to 7000 citations. 

Education and Training

  • Fellow, Pediatric Infectious Diseases, Pediatrics, Duke University, 1998 - 2001
  • Resident, Pediatrics, Children's Hospital, 1995 - 1998
  • Ph.D., University of North Carolina at Chapel Hill, 2003
  • M.P.H., University of North Carolina at Chapel Hill, 2001
  • M.D., University of Virginia, 1995

Selected Grants and Awards

Publications

Folgori, Laura, Julia Bielicki, Beatriz Ruiz, Mark A. Turner, John S. Bradley, Daniel K. Benjamin, Theoklis E. Zaoutis, et al. “Harmonisation in study design and outcomes in paediatric antibiotic clinical trials: a systematic review.” Lancet Infect Dis 16, no. 9 (September 2016): e178–89. https://doi.org/10.1016/S1473-3099(16)00069-4.

Full Text

Momper, Jeremiah D., Edmund V. Capparelli, Kelly C. Wade, Anand Kantak, Ramasubbareddy Dhanireddy, James J. Cummings, Jonathan H. Nedrelow, et al. “Population Pharmacokinetics of Fluconazole in Premature Infants with Birth Weights Less than 750 Grams.” Antimicrob Agents Chemother 60, no. 9 (September 2016): 5539–45. https://doi.org/10.1128/AAC.00963-16.

Full Text

Romaine, Andrew, Daniel Ye, Zachary Ao, Francia Fang, Octavious Johnson, Taylor Blake, Daniel K. Benjamin, et al. “Safety of histamine-2 receptor blockers in hospitalized VLBW infants.” Early Hum Dev 99 (August 2016): 27–30. https://doi.org/10.1016/j.earlhumdev.2016.05.010.

Full Text

Gonzalez, Daniel, Paula Delmore, Barry T. Bloom, C Michael Cotten, Brenda B. Poindexter, Elisabeth McGowan, Karen Shattuck, et al. “Clindamycin Pharmacokinetics and Safety in Preterm and Term Infants.” Antimicrob Agents Chemother 60, no. 5 (May 2016): 2888–94. https://doi.org/10.1128/AAC.03086-15.

Full Text

Gonzalez, Daniel, Debra L. Palazzi, Leena Bhattacharya-Mithal, Amira Al-Uzri, Laura P. James, John Bradley, Natalie Neu, et al. “Solithromycin Pharmacokinetics in Plasma and Dried Blood Spots and Safety in Adolescents.” Antimicrob Agents Chemother 60, no. 4 (April 2016): 2572–76. https://doi.org/10.1128/AAC.02561-15.

Full Text

Ericson, Jessica E., Victor O. Popoola, P Brian Smith, Daniel K. Benjamin, Vance G. Fowler, Reese H. Clark, and Aaron M. Milstone. “Burden of Invasive Staphylococcus aureus Infections in Hospitalized Infants.” Jama Pediatr 169, no. 12 (December 2015): 1105–11. https://doi.org/10.1001/jamapediatrics.2015.2380.

Full Text

Kelly, Matthew S., Daniel K. Benjamin, Karen M. Puopolo, Matthew M. Laughon, Reese H. Clark, Sagori Mukhopadhyay, P Brian Smith, and Sallie R. Permar. “Postnatal Cytomegalovirus Infection and the Risk for Bronchopulmonary Dysplasia.” Jama Pediatr 169, no. 12 (December 2015): e153785. https://doi.org/10.1001/jamapediatrics.2015.3785.

Full Text

Thaden, Joshua T., Jessica E. Ericson, Heather Cross, Stephen P. Bergin, Julia A. Messina, Vance G. Fowler, Daniel K. Benjamin, et al. “Survival Benefit of Empirical Therapy for Staphylococcus aureus Bloodstream Infections in Infants.” Pediatr Infect Dis J 34, no. 11 (November 2015): 1175–79. https://doi.org/10.1097/INF.0000000000000850.

Full Text

Offringa, Martin, Jonathan M. Davis, Mark A. Turner, Robert Ward, Ralph Bax, Sam Maldonado, Vikram Sinha, et al. “Applying Regulatory Science to Develop Safe and Effective Medicines for Neonates: Report of the US Food and Drug Administration First Annual Neonatal Scientific Workshop, October 28-29, 2014.” Ther Innov Regul Sci 49, no. 5 (September 2015): 623–31. https://doi.org/10.1177/2168479015597730.

Full Text

Arnold, Christopher J., Jessica Ericson, Nathan Cho, James Tian, Shelby Wilson, Vivian H. Chu, Christoph P. Hornik, et al. “Cefepime and Ceftazidime Safety in Hospitalized Infants.” Pediatr Infect Dis J 34, no. 9 (September 2015): 964–68. https://doi.org/10.1097/INF.0000000000000778.

Full Text

Pages